miR-99a suppresses the metastasis of human non-small cell lung cancer cells by targeting AKT1 signaling pathway

Journal of Cellular Biochemistry

Volumn 116, Issue 2, 2015, Pages 268-276

  Yu, Shi Huan ^a   Zhang, Chun Ling ^a   Dong, Fu Shi ^a   Zhang, Yi Mei ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

AKT1; Matrix metalloproteinase 2; microRNA; miR 99a; Non Small cell lung cancer

Indexed keywords

MICRORNA; MICRORNA 99A; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; MIRN99 MICRORNA, HUMAN; PROTEIN KINASE B;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STAGING; CANCER TISSUE; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER CELL LINE; MALE; METASTASIS; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR INVASION; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOBLOTTING; LUNG TUMOR; METABOLISM; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; LUNG NEOPLASMS; MALE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84916623582     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24965     Document Type: Article

References (38)

1. Arora S, Ranade AR, Tran NL, Nasser S, Sridhar S, Korn RL, Ross JT, Dhruv H, Foss KM, Sibenaller Z, Ryken T, Gotway MB, Kim S, Weiss GJ. 2011. MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int J Cancer 129:2621-2631.
2. Ataie-Kachoie P, Morris DL, Pourgholami MH. 2013. Minocycline suppresses interleukine-6, its system signaling pathways and impairs migration, invasion and adhesion capacity of ovarian cancer cells: In vitro and in vivo studies. PLoS ONE 8:e60817.
3. Barrette K, Van Kelst S, Wouters J, Marasigan V, Fieuws S, Agostinis P, van den Oord J, Garmyn M. 2014. Epithelial-mesenchymal invasion of cutaneous squamous cell carcinoma is paralleled by AKT activation. Br J Dermatol. DOI: 10.1111/bjd.12967.
4. Bartel DP. 2004. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116:281-297.
5. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. 2005. Activation of AKT kinases in cancer: Implications for therapeutic targeting. Adv Cancer Res 94:29-86.
6. Betel D, Wilson M, Gabow A, Marks DS, Sander C. 2008. The microRNA. org resource: Targets and expression. Nucleic Acids Res 36:D149-D153.
7. Cao Q, Li YY, He WF, Zhang ZZ, Zhou Q, Liu X, Shen Y, Huang TT. 2013. Interplay between microRNAs and the STAT3 signaling pathway in human cancers. Physiol Genomics 45:1206-1214.
8. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, Blanchard KL, Thomas JE. 2007. Atransforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448:439-444.
9. Centers for Disease Control and Prevention (CDC). 2006. Improved prevalence estimates for 18 selected major birth defects? United States, 1999-2001. MMWR Morb Mortal Wkly Rep 54:1301-1305.
10. Chen K, Rajewsky N. 2007. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet 8:93-103.
11. Cheng WY, Chiao MT, Liang YJ, Yang YC, Shen CC, Yang CY. 2013. Luteolin inhibits migration of human glioblastoma U-87 MG and T98G cells through downregulation of Cdc42 expression and PI3K/AKT activity. Mol Biol Rep 40:5315-5326.
12. Cheung M, Testa JR. 2013. Diverse mechanisms of AKT pathway activation in human malignancy. Curr Cancer Drug Targets 13:234-244.
13. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB, 3rd, Kaestner KH, Bartolomei MS, Shulman GI, Birnbaum MJ. 2001. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292:1728-1731.
14. Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ. 2001. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 276:38349-38352.
15. Easton RM, Cho H, Roovers K, Shineman DW, Mizrahi M, Forman MS, Lee VM, Szabolcs M, de Jong R, Oltersdorf T, Ludwig T, Efstratiadis A, Birnbaum MJ. 2005. Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol 25:1869-1878.
16. Gong M, Ma J, Guillemette R, Zhou M, Yang Y, Yang Y, Hock JM, Yu X. 2014. MiR-335 inhibits small cell lung cancer bone metastases via IGF-IR and RANKL pathways. Mol Cancer Res 12:101-110.
17. Gu W, Fang S, Gao L, Tan Y, Yang Z. 2013. Clinic significance of microRNA-99a expression in human lung adenocarcinoma. J Surg Oncol 108:248-255.
18. Heist RS, Engelman JA. 2012. SnapShot: Non-small cell lung cancer. Cancer Cell 21(448):e2.
19. Hu Y, Zhu Q, Tang L. 2014. MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression. PLoS ONE 9:e92099.
20. Jemal A, Center MM, DeSantis C, Ward EM. 2010. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19:1893-1907.
21. Jin Y, Tymen SD, Chen D, Fang ZJ, Zhao Y, Dragas D, Dai Y, Marucha PT, Zhou X. 2013. MicroRNA-99 family targets AKT/mTOR signaling pathway in dermal wound healing. PLoS ONE 8:e64434.
22. Kiesslich T, Berr F, Alinger B, Kemmerling R, Pichler M, Ocker M, Neureiter D. 2012. Current status of therapeutic targeting of developmental signalling pathways in oncology. Curr Pharm Biotechnol 13:2184-2220.
23. Kim MJ, Kang HG, Lee SY, Jeon HS, Lee WK, Park JY, Lee EB, Lee JH, Cha SI, Kim DS, Kim CH, Kam S, Jung TH, Park JY. 2012. AKT1 polymorphisms and survival of early stage non-small cell lung cancer. J Surg Oncol 105:167-174.
24. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. 2012. MicroRNAs in cancer management. Lancet Oncol 13:e249-e258.
25. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N. 2005. Combinatorial microRNA target predictions. Nat Genet 37:495-500.
26. Kuo YZ, Tai YH, Lo HI, Chen YL, Cheng HC, Fang WY, Lin SH, Yang CL, Tsai ST, Wu LW. 2014. MiR-99a exerts anti-metastasis through inhibiting myotubularin-related protein 3 expression in oral cancer. Oral Dis 20:e65-e75.
27. Lee MW, Kim DS, Lee JH, Lee BS, Lee SH, Jung HL, Sung KW, Kim HT, Yoo KH, Koo HH. 2011. Roles of AKT1 and AKT2 in non-small cell lung cancer cell survival, growth, and migration. Cancer Sci 102:1822-1828.
28. Li X, Yang Q, Yu H, Wu L, Zhao Y, Zhang C, Yue X, Liu Z, Wu H, Haffty BG, Feng Z, Hu W. 2014. LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway. Oncotarget 5:788-801.
29. Nagayama K, Kohno T, Sato M, Arai Y, Minna JD, Yokota J. 2007. Homozygous deletion scanning of the lung cancer genome at a 100-kb resolution. Genes Chromosomes Cancer 46:1000-1010.
30. Scheid MP, Woodgett JR. 2003. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett 546:108-112.
31. Shin DY, Lee WS, Jung JH, Hong SH, Park C, Kim HJ, Kim GY, Hwang HJ, Kim GS, Jung JM, Ryu CH, Shin SC, Hong SC, Choi YH. 2013. Flavonoids from Orostachys japonicus A. Berger inhibit the invasion of LnCaP prostate carcinoma cells by inactivating Akt and modulating tight junctions. Int J Mol Sci 14:18407-18420.
32. Strauss GM. 2005. Adjuvant chemotherapy of lung cancer: Methodologic issues and therapeutic advances.Hematol Oncol Clin North Am 19:263-281,vi.
33. Tian T, Nan KJ, Guo H, Wang WJ, Ruan ZP, Wang SH, Liang X, Lu CX. 2010. PTEN inhibits the migration and invasion of HepG2 cells by coordinately decreasing MMP expression via the PI3K/Akt pathway. Oncol Rep 23:1593-1600.
34. Turcatel G, Rubin N, El-Hashash A, Warburton D. 2012. MIR-99a and MIR-99b modulate TGF-beta induced epithelial to mesenchymal plasticity in normal murine mammary gland cells. PLoS ONE 7:e31032.
35. Yen YC, Shiah SG, Chu HC, Hsu YM, Hsiao JR, Chang JY, Hung WC, Liao CT, Cheng AJ, Lu YC, Chen YW. 2014. Reciprocal regulation of microRNA-99a and insulin-like growth factor I receptor signaling in oral squamous cell carcinoma cells. Mol Cancer 13:6.
36. Zhang J, Jin H, Liu H, Lv S, Wang B, Wang R, Liu H, Ding M, Yang Y, Li L, Zhang J, Fu S, Xie D, Wu M, Zhou W, Qian Q. 2014. MiRNA-99a directly regulates AGO2 through translational repression in hepatocellular carcinoma. Oncogenesis 3:e97.
37. Zhang WC, Liu J, Xu X, Wang G. 2013. The role of microRNAs in lung cancer progression. Med Oncol 30:675.
38. Zhao B, Han H, Chen J, Zhang Z, Li S, Fang F, Zheng Q, Ma Y, Zhang J, Wu N, Yang Y. 2014. MicroRNA inhibits migration and invasion of human nonsmall cell lung cancer by targeting ITGB3 and MAP4K3. Cancer Lett 342:43-51.